The immunostimulatory effect of CpG oligodeoxynucleotides on peripheral blood mononuclear cells of healthy dogs and dogs with atopic dermatitis

Lee, Annette Jassies-van der; Rutten, Victor P.M.G.; Spiering, Rachel; Kooten, Peter van; Willemse, Ton; Broere, Femke

doi:10.1016/j.tvjl.2013.12.016

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to in vitro studies evaluating the effects of CpG ODN on the PBMCs of atopic dogs (Rostaher‐Prélaud and others 2013, Jassies‐van der Lee and others 2014), neither an increase in Th1 nor in regulatory cytokine serum concentration and mRNA expression could be detected. However, apart from TGF‐β, cytokine concentrations in the serum samples were below the detection threshold, thus a thorough evaluation of the immunological effects of CpG GNP immunotherapy on serum cytokines was not possible.…”

Section: Discussionmentioning

confidence: 60%

“…Furthermore, differentiation of B cells to plasma cells and isotype switching to IgG is promoted (Krieg 2006, Jarnicki and others 2008, Fonseca and Kline 2009). In atopic dogs, CpG ODN also induce a Th1-biased immune response and increase the expression of IL-10 mRNA in vitro (Kurata and others 2004, Rostaher-Prélaud and others 2013, Jassies-van der Lee and others 2014). These effects resemble those observed in the course of AIT (Foster and others 2002, Shida and others 2004, Keppel and others 2008).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preliminary evaluation of cytosine‐phosphate‐guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

Wagner¹,

Geh²,

Hubert³

et al. 2017

Veterinary Record

View full text Add to dashboard Cite

Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1.5 mg GNP) were injected subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis factor-α, transforming growth factor-β, interleukin (IL) 10 and IL-4 (only mRNA expression) were determined at inclusion and after 8 weeks (group 1+2) and 18 weeks (group 2). Lesions and pruritus improved significantly from baseline to week 8. Mean improvements from baseline to week 18 were 23 per cent and 44 per cent for lesions and pruritus, respectively, an improvement of ≥50 per cent was seen in six out of nine and three out of six dogs, respectively. IL-4 mRNA expression decreased significantly. The results of this study show a clinical improvement of canine AD with CpG GNP comparable to allergen immunotherapy. Controlled studies are needed to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Preliminary evaluation of cytosine‐phosphate‐guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

Wagner¹,

Geh²,

Hubert³

et al. 2017

Veterinary Record

View full text Add to dashboard Cite

show abstract

“…AD in dogs is an allergic skin disease with a prevalence of 10–15% and many similarities with human AD [ 3 ]. The cause of the onset of canine AD remains unclear, although it is usually presumed to be due to skin barriers or immunological changes resulting from various interactions, such as an imbalance in immune function, as in humans [ 3 , 4 , 5 ]. Currently, canine AD drugs have different clinical efficacy in different breeds, potentially because multiple gene abnormalities and altered immunological processes can be involved [ 3 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Canine Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Attenuate Atopic Dermatitis

Cho¹,

Kim

Kim³

et al. 2023

Animals

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is associated with systemic inflammation and immune modulation. Previously, we have shown that extracellular vesicles resulting from human adipose-tissue-derived mesenchymal stem cells (ASC-EVs) attenuated AD-like symptoms by reducing the levels of multiple inflammatory cytokines. Here, we aimed to investigate the improvement of canine AD upon using canine ASC-exosomes in a Biostir-induced AD mouse model. Additionally, we conducted in vivo toxicity studies to determine whether they targeted organs and their potential toxicity. Firstly, we isolated canine ASCs (cASCs) from the adipose tissue of a canine and characterized the cASCs-EVs. Interestingly, we found that cASC-EVs improved AD-like dermatitis and markedly decreased the levels of serum IgE, ear thickness, inflammatory cytokines, and chemokines such as IL-4 and IFN-γ in a dose-dependent manner. Moreover, there was no systemic toxicity in single- or repeat-dose toxicity studies using ICR mice. In addition, we analyzed miRNA arrays from cASC-EVs using next-generation sequencing (NGS) to investigate the role of miRNAs in improving inflammatory responses. Collectively, our results suggest that cASC-EVs effectively attenuate AD by transporting anti-inflammatory miRNAs to atopic lesions alongside no toxicological findings, resulting in a promising cell-free therapeutic option for treating canine AD.

show abstract

Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs

Yannelli

Wouda

Masterson³

et al. 2016

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

The immunostimulatory effect of CpG oligodeoxynucleotides on peripheral blood mononuclear cells of healthy dogs and dogs with atopic dermatitis

Cited by 5 publications

References 36 publications

Preliminary evaluation of cytosine‐phosphate‐guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

Preliminary evaluation of cytosine‐phosphate‐guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis

Canine Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Attenuate Atopic Dermatitis

Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs

Contact Info

Product

Resources

About